Immune Disorders

A recent study shows a high neutrophil-to-lymphocyte ratio may predict poor response to ursodeoxycholic acid in primary biliary cholangitis (PBC).

In addition to helping your loved one manage PBC symptoms, it is just as important to provide moral and emotional support.

The FDA has accepted a New Drug Application (NDA) for elafibranor, an investigational therapeutic for the treatment of primary biliary cholangitis (PBC).

Treatment with elafibranor may improve bile flow in patients with primary biliary cholangitis (PBC), according to results of a phase 3 trial.

As there is no cure for primary biliary cholangitis (PBC), a holistic approach is recommended to complement medical care.

While it’s most commonly found in women ages 35 to 55, primary biliary cholangitis (PBC) has also been reported in younger patients.

Treatment of primary biliary cholangitis (PBC) with obeticholic acid may reduce negative outcomes in the disease, according to a study.

Seeking a Priority Review designation, CymaBay anticipates that the FDA will conclude its evaluation of the PBC treatment within six months.

There are many associations and organizations that offer support for people living with PBC and provide information about ongoing research in the field.

There is no question that primary biliary cholangitis (PBC) overwhelmingly affects women, but no explanation for this has yet been found.